key: cord-0954887-sshvwdr5
authors: Webb, Gwilym J.; Moon, Andrew M.; Barnes, Eleanor; Barritt, A. Sidney; Marjot, Thomas
title: Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients.
date: 2021-02-05
journal: J Hepatol
DOI: 10.1016/j.jhep.2021.01.036
sha: fa2159ab8d3f0382d7efd422fc52ad46c35ddb06
doc_id: 954887
cord_uid: sshvwdr5

nan

Our understanding of the impact of COVID-19 on liver transplant recipients has recently advanced significantly. In August 2020 Colmenero et al. published data on behalf of the Spanish Liver Transplant Society (SETH) in Journal of Hepatology [1] . The authors reported 111 LT recipients with SARS-CoV-2 infection and concluded that these patients were at no greater risk of severe COVID-19 than the general population. Furthermore, within LT recipients, comorbidity, male sex, and mycophenolate mofetil (MMF) use were reported as associated with severe disease. We congratulate our Spanish colleagues for rapidly conducting their comprehensive study in the midst of the pandemic.

Helpfully, Colmenero et al. provided an extract of their dataset: an important gesture in an era of rapid-fire reports. Having examined this, we feel a number of points would benefit from further exploration. We have also made comparisons with our own analysis of 151 LT recipients with SARS-CoV-2 infection (data extract supplied) [2] . A key difference is that Colmenero et al. used a composite endpoint of death, intensive care unit (ICU) admission, or mechanical ventilation, whereas we used death alone; neither showed a significant difference between LT and non-LT patients. This is in contrast to the high rates of mortality in patients with cirrhosis. [3] The first point of note is that only 4/20 (20%) SETH patients who died were admitted to ICU, compared to 22/28 (79%) in our cohort; overall mortality was similar at 18% and 19% respectively. Although the reasons for this are not apparent, those who died in the SETH cohort without ICU admission were older and had higher Charlson Comorbidity Indices (CCI) which may suggest that ICU admission was thought inappropriate. Within our cohort, 9% of LT recipients deemed in need of ICU due to severe enough disease were not admitted due to this being deemed inappropriate. ICU admission reflects a combination of patient and clinician factors and is therefore an imperfect marker of COVID-19 disease severity.

Second, although Colmenero et al. report a univariable association between age and severe COVID-19, their multivariable analysis shows no significant association with age in contrast to the general literature [4, 5] . On closer analysis, the authors have included age both alone and as a component of the CCI in their analysis thus masking age as an independent variable. The same issue exists for diabetes and renal function, which are both components of the CCI [6] .

Third, Colmenero et al. reported a correlation between male sex and severe COVID-19 consistent with findings from other large non-LT datasets [7] . However, comparing their table 1, table 2 , and the raw dataset demonstrates that the association of poor outcome is in fact with female sex [12/79 (15%) men died vs. 8/32 (25%) women] and that there has been a transcription error.

Fourth, the multivariable analysis includes a number of variables that change over the disease course of COVID-19, such as immunosuppression withdrawal, and oxygen saturations at diagnosis. Patients were diagnosed with SARS-CoV-2 at varying time points, with time from diagnosis to ICU admission ranging from -1 to 11 days, with ICU admission not being universal as above. Furthermore, patients not hospitalised were excluded. This makes the use of a composite endpoint and time-dependent analysis (e.g. Cox regression) more difficult to interpret.

Considering the points above, we re-examined the SETH dataset in relation to the single end-point of death. We adjusted reported CCIs to remove age, and only considered baseline variables. To permit comparison, we retrospectively applied the same calculations to our own cohort, using diagnosis as the point-of-entry for both cohorts. We then performed a multivariable logistic regression analysis in each cohort and both cohorts combined, with death as the dependent variable and age, sex, CCI (without age), hypertension, and baseline tacrolimus, azathioprine, ciclosporin, MMF, everolimus, and corticosteroid use as independent variables (Fig 1A) . When analysed in this way, with backwards selection at p<0.1, age and CCI were significantly associated with death whereas no significant associations remained with immunosuppressive regimen (Fig 1A) . A limitation of our registry was that the precise duration from laboratory diagnosis to death was not known, thus preventing a time dependent analysis from being performed. Our instructions to submitting physicians specified that patients should be followed until mortality or resolution of COVID-19 and both cohorts allowed inclusion of patients presenting at any time point.

To explore the relationship between age, co-morbidity and death we plotted age against CCI according for both LT cohorts (Fig 1B & 1C) . Notably, no patient from either cohort with a CCI of 0 died. Conversely, patients who died were older with higher CCIs. For the SETH cohort, the CCI threshold for death was <3.

In our cohort, 6 patients died with a CCI <3 however in 4 cases an additional important cofactor not J o u r n a l P r e -p r o o f captured by CCI was identified (Fig. 1C) . The pattern of increasing mortality with age and CCI in both cohorts was similar to that observed in our non-LT comparison cohort (Fig. 1D) .

Considering the above, age and comorbidity appear key in determining outcome from SARS-CoV-2 infection in the LT population. The fact that both published datasets have similar findings supports their generalisability. Although immunosuppression regimen may be of additional importance, it appears unlikely to confer more risk than 10 years of additional age. Further formal work with larger/combined datasets is required before medication changes can be recommended. 

Epidemiological pattern, incidence and outcomes of COVID-19 in liver transplant patients

Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Assessing the age specificity of infection fatality rates for COVID-19: Meta-analysis & public policy implications

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Factors associated with COVID-19-related death using OpenSAFELY

Financial support: The COVID-Hep.net registry was supported by the European Association for the Study of the Liver (EASL; grant number 2020RG03). SECURE-cirrhosis was also supported by the National Data availability statement: an extract from the COVID-Hep.net and SECURE-Cirrhosis registries representing the data used to produce this analysis is provided alongside the manuscript. Additional data may be available on request to the corresponding author.